Director/PDMR Shareholding

RNS Number : 5625L
Dechra Pharmaceuticals PLC
06 September 2019
 



 

 

 

6 September 2019

 

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

LEI: 213800J4UVB5OWG8VX82

 

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

 

 

 

The Company announces that on 6 September 2019 the following Directors were granted awards over Ordinary Shares of 1 pence each in the Company under the Dechra 2017 Long Term Incentive:

 

Name of individual

Director

Type of award

Number of shares subject to award

Ian Page

Director

LTIP Award - nil cost option

35,087

Tony Griffin

Director

LTIP Award - conditional award

10,984

 

 

The vesting of all the above awards is subject to the achievement of performance targets. In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period. Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance condition. If the ROCE performance condition is not met, then the LTIP Awards will lapse in full.



The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Ian Page

 

2.

Reason for the notification

a)

Position/status

Director

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

ISIN: GB0009633180

b)

Nature of the transaction

Grant of an award over Ordinary Shares under the Company's Long Term Incentive Plan

c)

Price(s) and volumes(s)

Nil cost option

 

Price

Volume

Nil cost award

35,087

 

 

d)

Aggregated information

-   Aggregate volume

 

-   Price

 

 

 

Awards granted over 35,087 Ordinary Shares in total

 

N/A

 

e)

Date of the transaction

2019-09-06

f)

Place of the transaction

Outside a trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Tony Griffin

 

2.

Reason for the notification

a)

Position/status

Director

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

ISIN: GB0009633180

b)

Nature of the transaction

Grant of an award over Ordinary Shares under the Company's Long Term Incentive Plan

c)

Price(s) and volumes(s)

Conditional award

 

Price

Volume

Nil cost award

10,984

 

 

d)

Aggregated information

-   Aggregate volume

 

-   Price

 

 

 

Awards granted over 10,984 Ordinary Shares in total

 

 

N/A

 

e)

Date of the transaction

2019-09-06

f)

Place of the transaction

Outside a trading venue

 

 

For further information, please contact:

 

Melanie Hall, Company Secretary                 

Telephone number: 01606 814730

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHCKADQQBKDNCK
UK 100

Latest directors dealings